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Review Neuroinflammation in inflammatory bowel disease
Shaheen E Lakhan* and Annette Kirchgessner
Abstract
Inflammatory bowel disease is a chronic intestinal inflammatory condition, the pathology of which is incompletely 
understood. Gut inflammation causes significant changes in neurally controlled gut functions including cramping, 
abdominal pain, fecal urgency, and explosive diarrhea. These symptoms are caused, at least in part, by prolonged 
hyperexcitability of enteric neurons that can occur following the resolution of colitis. Mast, enterochromaffin and other 
immune cells are increased in the colonic mucosa in inflammatory bowel disease and signal the presence of 
inflammation to the enteric nervous system. Inflammatory mediators include 5-hydroxytryptamine and cytokines, as 
well as reactive oxygen species and the production of oxidative stress. This review will discuss the effects of 
inflammation on enteric neural activity and potential therapeutic strategies that target neuroinflammation in the 
enteric nervous system.
Introduction
Inflammatory bowel disease (IBD), which is comprised of
two main types, ulcerative colitis (UC) and Crohn's dis-
ease (CD), affects approximately 3.6 million people in the
United States and Europe. An alarming rise in previous
low-incidence areas, such as Asia, is currently being
observed [1]. Although considerable progress has been
made in recent years, a major gap in knowledge of the
pathogenesis of IBD remains. Without further research
on the pathogenesis of IBD, the discovery of lasting,
effective forms of treatment is impossible. Moreover, pre-
dicting disease outcome remains a challenge.
IBD is characterized by chronic or relapsing immune
activation and inflammation within the gastrointestinal
(GI) tract that markedly alters GI function [2]. In CD all
layers of the gut may be involved, and normal healthy gut
may be found between sections of diseased bowel. In con-
trast, UC causes inflammation and ulcers in the top layer
lining the large intestine. When the gut is inflamed, there
is breakdown of intestinal barrier function, abnormal
secretion, changes in the patterns of motility, and visceral
sensation, which contributes to symptom generation.
Typically, alterations in gut function that accompany GI
inflammation give rise to diarrhea, cramping, and pain,
all standard IBD symptoms.
Other chronic inflammatory diseases of the gut, includ-
ing celiac disease [3], an autoimmune reaction to gluten
found in wheat and other grains, and irritable bowel syn-
drome (IBS) [4], are characterized by abdominal pain and
GI dysfunction. There is clinical overlap between IBD
and IBS, with IBS-like symptoms frequently reported in
patients before the diagnosis of IBD, and a higher than
expected percentage reports of IBS symptoms in patients
in remission from established IBD [5]. There is growing
e v i d e n c e  t h a t  o c c u l t  i n f l a m m a t i o n  i n  t h e  G I  m u c o s a ,
rather than coexistent IBS may play an important role in
IBS-like symptoms in patients with IBD who are thought
to be in clinical remission [5].
Inflammation is well known to affect gut function.
Experimental data suggest that inflammation, even if
mild, could lead to persistent changes in GI nerve and
smooth muscle function, resulting in colonic dysmotility,
hypersensitivity, and dysfunction even when the preced-
ing infection is restricted to the proximal small intestine.
Furthermore, alterations in gut function are observed
after resolution of an acute intestinal inflammation, sug-
gesting that inflammation-induced changes persist fol-
lowing recovery and play a major role in the generation of
symptoms associated with IBD [6,7].
Data obtained from biopsies from patients with IBD
and animal models of IBD have consistently suggested a
role of inflammatory effects on enteric neurons in the
generation of symptoms associated with IBD [8,9]. The
enteric nervous system (ENS), the intrinsic innervation of
the bowel, controls virtually all GI functions (e.g., motil-
ity, secretion, blood flow, mucosal growth and aspects of
the local immune system). It is presently unknown
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whether the persistent alterations in gut function
observed following inflammation are due to altered prop-
erties of enteric nerves.
This review will provide a brief overview of the current
understanding of enteric neural abnormalities evoked by
gut inflammation, particularly in IBD. Despite advances
in the understanding of the pathophysiology of IBD, ther-
apeutic options for combating functional changes that
persist following transient GI inflammation are not avail-
able. Neuroprotective agents that can curtail the effects
of inflammation on GI nerves may show potential in the
treatment of chronic inflammatory diseases of the bowel.
The enteric nervous system
The ENS is a component of the autonomic nervous sys-
tem with the unique ability to function independently of
the central nervous system (CNS) (see [10] for a review).
The ENS regulates and coordinates almost all aspects of
intestinal function including gut motility, the transport of
fluid and electrolytes, the secretion of mucins, the pro-
duction of cytokines, and the regulation of epithelial bar-
r i e r  f u n c t i o n .  E a c h  o f  t h e  a s p e c t s  o f  p h y s i o l o g y  a r e
compromised in IBD and it is therefore not surprising
that there is an increasing amount of research interest in
elucidating the role of the ENS in the pathogenesis of
IBD.
Enteric ganglia are organized into two major ganglion-
ated plexuses, the myenteric (Auerbach's) and submu-
cosal (Meissner's) plexus. They contain a variety of
functionally distinct neurons, including primary afferent
neurons, interneurons, and motor neurons, synaptically
linked to each other in microcircuits. In addition, enteric
neurons are supported by glial cells, the ENS counter-
parts of astrocytes of the CNS, that can modulate enteric
neuron function. Neurons of the ENS also exist in close
apposition to cells of the mucosal immune system and the
intestinal epithelium and bi-directional communication
is known to occur at both of these interfaces.
Enteric neurons are known to control virtually all GI
functions, including motility, secretion, blood flow,
mucosal growth and aspects of the local immune system.
Consequently, permanent or even transient structural
alterations in the ENS, as occur in IBD, disrupt normal GI
function.
Effects of inflammation on enteric neurons
Patients with IBD manifest symptoms suggestive of dis-
turbed gut function, such as sensory-motor changes and
altered secretion. These abnormalities illustrate the
impact of inflammatory signals generated within the gut
mucosa on neural signaling in the ENS.
Inflammation-related alterations in the ENS can be
divided into those that occur in the structural morphol-
ogy of the ENS and those that occur in the levels of
enteric neurotransmitters. Several studies have demon-
strated ENS structural changes in human IBD (for
review, see [9,11]). Tissue analysis of patients with CD
or UC showed the existence of ENS abnormalities
including ganglia and nerve bundles of increased size
(hypertrophy) and/or number (hyperplasia) [9,12-14], as
well as changes to glial cells (hyperplasia), including
increased expression of the major histocompatability
complex class II antigens [9].
Although changes in the morphology of the ENS are
observed in both CD and UC, structural changes are
m o r e  m a r k e d  i n  C D  t h a n  t h e y  a r e  i n  U C  [ 1 3 ] .  N e rv e
trunk hypertrophy and hyperplasia have been reported
mainly for the mucosa, submucosa and myenteric plexus
of the ileum and colon of patients with CD, and these
structural abnormalities are associated with the extent of
inflammatory infiltrate. Mucosal and submucosal abnor-
malities are less commonly observed in patients with UC.
In fact, based on electron microscopic examination, it has
been suggested that severe and extensive necrosis of gut
axons may differentiate CD from other inflammatory dis-
orders [14]. Recurrence of CD after ileal or colonic resec-
tion is common.
The natural history of IBD progressively leads to the
development of complications in approximately two-
thirds of CD patients and less than one-third of UC
patients [15]. In CD, the main complications are the
development of fibrotic strictures that lead to intestinal
obstruction and the development of intra-abdominal and
peri-anal fistulae and abscesses. Recently, the presence of
myenteric and submucosal plexitis were shown to be pre-
dictive of early endoscopic CD recurrence [16,17]. Thus,
structural changes in the ENS are predictive of disease
evolution suggesting that neuroprotection would
decrease disease severity and may play a role in recur-
rence in CD.
Ganglion cell and nerve process degeneration and
necrosis often accompany ENS structural changes in IBD.
These findings have been confirmed in tissues from both
CD and UC patients showing swollen, empty axons, filled
with large membrane-bound vacuoles, swollen mito-
chondria, and concentrated neurofibrils [18]. Interest-
ingly, these abnormalities in gut structure may also be
observed in affected and non-affected areas of CD.
Structural ENS abnormalities -- including axonal
hypertrophy and neuronal cell death -- have been
observed in a variety of experiment animal models of
colitis [19]. Animal models have been developed to better
understand the pathophysiology of colitis, and are fre-
quently used to evaluate new anti-inflammatory strate-
gies. However, acute animal models of colitis do not
exactly mimic human IBD since acute inflammation is a
nonspecific pathological process in IBD. Nevertheless,
there is a close relationship between inflammation andLakhan and Kirchgessner Journal of Neuroinflammation 2010, 7:37
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ENS structural changes and animal models of colitis,
which can be used to elucidate the mechanisms underly-
ing ENS dysfunction, whose understanding would be
rather difficult in human diseases.
Experimental models of colitis have reported either no
change in cell numbers or a significant loss of enteric
neurons [20]. For example, Linden et al. reported that the
number of myenteric neurons per ganglion are signifi-
cantly decreased in trinitrobenzene sulfonic acid
(TNBS)-induced colitis in guinea pigs [21]. TNBS-
induced colitis results in a Th1-dominant inflammation
with excessive production of IFN-γ, TNF-α, and IL-12.
This model presumably resembles CD because of the
mucosal inflammation mediated by a Th1 response.
TNBS colitis is generally induced by intrarectal applica-
tion of TNBS in ethanol [22].
TNBS colitis is associated with a 20% loss of myenteric
neurons, which occurs at the time neutrophils infiltrate
the ganglia. Interestingly, this neuronal loss persisted at a
56-day time-point, when inflammation had resolved [21].
The decrease in myenteric neurons was not associated
with a decrease in any particular subpopulation of neu-
rons, suggesting an indiscriminant loss of neurons that
occurs during the onset of TNBS-colitis. In addition, the
neurotoxic insult was followed by rapid regeneration of
axons from the surviving neurons. Inflammation was also
associated with a significant loss of myenteric neurons in
rats with TNBS-induced colitis [23].
Similar findings were reported in 2,4-dinitrobenzene-
sulfonic acid (DNBS)-induced colitis in rats, where there
was a 50% decrease of neuronal cells in the myenteric
plexus [24]. Histopathological observation has shown
that DNBS-induced damages resemble human UC [25].
Cell death was observed as early as 48 hours after the
induction of colitis; a reduction which persisted for the 35
days of the study [24].
Significant neuronal death was also observed in
Trichinella spiralis murine colitis and Trichinella spiralis-
induced colitis in rats [26,27]. Intracolonic administration
of Trichinella spiralis larvae in rats causes colitis with fea-
tures similar to UC, notably with inflammation predomi-
nantly limited to the colonic mucosa [26]. Interestingly, in
this animal model of colitis, there was a significant loss of
nitric oxide synthase- (NOS-) immunoreactive neurons
in the myenteric plexus of infected rats. Moreover, the
selective loss of NOS-positive neurons appears to under-
lie changes in motility.
Why there are such differences in findings regarding
alterations in numbers of nerve cells in human patients
and animal models of IBD is uncertain, but it may be due
to the duration of time over which the inflammation
develops, with the rapid onset of inflammation in models
employing chemicals such as TNBS and DNBS [28].
The mechanism of induction of neuronal cell death
remains unknown; however, the loss of neurons was asso-
ciated with the appearance of eosinophilic and neutro-
philic infiltrates into myenteric ganglia suggesting that it
may be mediated by interactions with the mucosal
immune system [24].
Myenteric ganglionitis, associated with infiltrates of
lymphocytes such as plasma cells and mast cells is fre-
q u e n t l y  o b s e r v e d  i n  h u m a n s  [ 2 9 , 3 0 ]  a n d  e x p e r i m e n t a l
colitis, including murine Trichinella spiralis-induced
colitis [27]. Following TNBS colitis, eosinophils and T
cells are commonly found adjacent to myenteric ganglia.
This indicates a specific targeting to enteric ganglia [31].
Eosinophils are first observed adjacent to myenteric gan-
glia at six hours, and T cells are observed at twenty-four
hours. There are no eosinophils associated with myen-
teric ganglia in normal intestine, and T cells are rarely
found in the vicinity. Thus, their presence in elevated
numbers is an indication of ganglionitis and suggestive of
neuropathology. In addition to ganglia, immune cells
have also been observed in smooth muscle layers in coli-
tis [27,32].
The therapeutic efficacy of leukocyte inhibitors has
been demonstrated in murine models of colitis. In addi-
tion, in patients with IBD, the anti-inflammatory effects
of 5-aminosalicylic acid compounds [33] and corticoster-
oids [34] have been ascribed, at least in part, to their abil-
ity to inhibit the formation of and/or scavenging of
reactive oxygen metabolites from neutrophils and to
reduce neutrophil infiltration, respectively. Interestingly,
reducing neutrophil granulocyte infiltration into the
intestinal mucosa by pretreatment of mice with anti-neu-
trophil serum results in partial attenuation of myenteric
plexus cell loss following DNBS colitis [35]. Moreover,
resolution of the inflammatory process is associated with
a gradual improvement in propulsive action.
Mechanisms of cell death
Inappropriate neuronal cell death occurs in various neu-
rodegenerative and inflammatory conditions of the ner-
vous system. While the mechanisms of neuronal cell loss
have not been studied in animal models of colitis or in
patients with IBD, investigation of neurodegenerative and
inflammatory conditions of the central and peripheral
nervous systems have frequently demonstrated activation
of apoptotic pathways.
Caspase-3 is a pivotal mediator of apoptosis because of
its ability to cleave a vast array of proteins. Active cas-
pase-3 consists of 17 and 11 kDa subunits derived from a
32 kDa pro-enzyme by cleavage at multiple aspartic acid
sites. Its cleavage results in the functional loss of multiple
proteins, leading to the death of the cell.
Recently, De Giorgio et al. demonstrated neuronal
apoptosis in guinea pig myenteric plexus neuron cultures
[36]. Furthermore, this myenteric neuronal cell loss was
mediated through activation of a caspase-3-dependent
pathway. Strongly activated caspase-3 and cleaved polyLakhan and Kirchgessner Journal of Neuroinflammation 2010, 7:37
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(ADP-ribose) polymerase immunoreactivities were evi-
dent as early as 30 minutes following instillation of dini-
trobenzene sulfonic acid (DNBS) to induce experimental
colitis. Lourenssen et al. recently demonstrated that the
caspase inhibitor zVAD, but not DEVD, significantly pre-
vents neuronal death, implying a largely caspase-3/7
independent mechanism of apoptotic death. This finding
was supported by staining for annexin V and cleaved cas-
pase-3 [37].
Transglutaminases are a large family of related and
ubiquitous enzymes which catalyze the cross linking of a
glutaminyl residue of a protein/peptide substrate to a
lysyl residue of a protein/peptide co-substrate [38]. These
enzymes are also capable of catalyzing other reactions
that are important for cell life. Recently, "tissue" transglu-
taminase (tTG) was shown to be involved in molecular
mechanisms responsible for very widespread human
pathology in celiac disease, in addition to a number of
human neurodegenerative diseases.
Experimental colitis upregulates tTG and increases its
activity in the ENS [23]. One week after TNBS-induction
of colitis in rats, myenteric neurons display increased tTG
compared to control and non-inflamed colon. Similarly,
tTG activity is significantly higher in inflamed colon. In
cultured myenteric neurons incubated with retinoic acid,
a tTG inducer, significantly increased neuronal apoptosis
suggests that tTG enhances neuronal susceptibility to
apoptosis. These data pave the way to future therapeutic
options targeting neuronal apoptosis as a pathogenic fac-
tor that could contribute to neuropathologic changes
during gut inflammation.
Neurochemical and receptor changes
Overall, a considerable body of evidence from animal
models and patients with IBD shows that dramatic altera-
tions occur in the ENS in conditions of inflammation,
and are coupled with disturbed motility that are likely to
play an important role in the pathogenesis of the disease.
Evidence in animal models of IBD shows that, in addi-
tion to gross changes in the morphology and architecture
of neural ganglia and nerve cell bodies, subtle changes in
the expression of neurotransmitters or their receptors at
synapses within the gut wall are a prevalent and impor-
tant aspect of intestinal inflammation. Inflammatory cells
in the intestine, such as dendritic cells, lymphocytes,
macrophages and mast cells, express receptors for small
molecule neurotransmitters and neuropeptides, and
enteric neurons are responsive to cytokines that inflam-
matory cells secrete.
Chemical messengers that have been implicated in IBD
include neuropeptides and small molecules such as ace-
tylcholine (ACh) and 5-hydroxytryptamine (5-HT or
serotonin) [39]. In the rodent intestine, inflammation
markedly affects the cholinergic neurons that comprise
the major excitatory phenotype of the ENS, causing
decreased release of ACh [40]. This may be derived from
changes in the expression of the synaptic vesicle proteins
that are necessary for neurotransmitter release, such as
the selective decrease of the synaptic vesicle protein neu-
ronal calcium sensory 1 during TNBS-induced colitis
[12]. 5-HT, a major gastrointestinal paracrine hormone
and enteric neurotransmitter known to be involved in the
initiation of peristaltic activity, has recently been recog-
nized to be a pro-inflammatory neurotransmitter as well,
and its secretion is increased in the enterochromaffin
cells of patients with CD [41].
Substance P (SP), which belongs to a family of structur-
ally linked peptides known as tachykinins, is an 11-amino
acid peptide secreted by nerves and inflammatory cells
such as monocytes, macrophages, eosinophils, and lym-
phocytes, and acts by binding to the neurokinin-1 (NK-1)
receptor [28]. In addition to a variety of modulatory
effects (i.e., smooth muscle contraction, vasodilation, and
epithelial ion transport), SP is a mediator of neurogenic
inflammation and plays an important role [28] in inflam-
matory diseases of the respiratory, gastrointestinal, and
musculoskeletal systems [28].
Elevated SP and upregulated NK-1 receptor expression
have been reported in the rectum and colon of patients
with IBD [42]. SP increases dramatically in the myenteric
plexus of the colon of patients with UC and involves a
shift from a mainly cholinergic to a more extensive SP
innervation [43,39]. In fact, the density of SP nerve termi-
nals in the lamina propria of UC patients correlates with
the severity of the disease. Interestingly, similar changes
in neurochemical coding were also observed in non-
inflamed areas of bowel and may constitute part of the
neuronal basis for the altered motility disturbance
observed during UC [43]. There is also an increased
expression of SP binding sites in the inflamed mucosa of
UC patients [44] as well as an increase in NK-1 receptor
mRNA [19]. As a result of these findings, tachykinin
antagonists have been proposed as potential anti-inflam-
matory compounds [45].
In support of the idea that SP is pro-inflammatory and
plays a role in the pathogenesis of IBD, specific antago-
nists for the high-affinity NK1 receptor decrease inflam-
mation and severity of DSS-induced colitis, protect from
dinitrofluorobenzene- (DNFB-) induced colitis in mice
[42] and protect SCID mice against T-cell induced
chronic colitis [46]. In addition, blocking NK1 receptors
also results in reductions in colitis in acetic acid-induced
colitis and Clostridium difficile ileitis. Neuron-derived
pro-inflammatory SP can stimulate macrophages, mast
cells, and endothelium to release cytokines, which can
contribute to and sustain an inflammatory infiltrate,
thereby causing tissue damage and neurodegeneration.
Since NK-1 promotes inflammation, NK-1 antagonistsLakhan and Kirchgessner Journal of Neuroinflammation 2010, 7:37
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are candidates to be therapeutic agents for IBD. However,
whether they attenuate the effects of inflammation in the
ENS is unknown.
Considerable evidence suggests that vasoactive intesti-
nal peptide (VIP) also participates in the pathophysiology
of IBD [47]. VIP is a 28-amino-acid peptide belonging to
the pituitary adenylate cyclase-activating polypeptide
(PACAP)/glucagon superfamily based on sequence
homologies. All layers of the colon contain VIP with the
highest concentration in the myenteric plexus. Function-
ally, VIP inhibits the peristaltic reflex in the circular mus-
cle layer, controls intestinal blood flow, and modulates
the immune system by binding to two G-protein-coupled
VIP receptor -- VPAC1 and VPAC2 -- which are also
shared by PACAP . VIP is released from nerve terminals
that contain nitric oxide synthase (NOS). Together, these
two peptides are believed to be the primary components
of non-adrenergic, non-cholinergic nerve transmission in
the gut.
Several pieces of evidence indicate that VIP participates
in the pathophysiology of colitis and IBD. Treatment with
VIP after the onset of TNBS-induced colitis in mice
reduces the clinical and histopathologic severity of colitis
as well as Th1 cytokine levels [48]. In addition, glucagon-
like peptide 2 (GLP-2), an important regulator of nutri-
tional absorptive capacity with anti-inflammatory
actions, reduces intestinal mucosal inflammation in
TNBS-induced colitis in rats by activation of VIP neurons
of the submucosal plexus [49]. These findings indicate the
potential use of VIP in the therapy of CD; however, VIP
has potential side effects, including hypotension and
diarrhea, when given at high doses.
Significant increases in VIP content of colonic nerves
have been reported in biopsies from CD patients com-
pared to UC patients or controls [50]. A similar increase
in VIP concentration was also evident in rectal biopsies
from CD, but not UC, patients. Similar findings have
been reported in the myenteric plexus in guinea-pig
TNBS colitis [21]. Kishimoto et al. reported an increased
VIP immunoreactivity in neurons and nerve fibers in
both plexuses of the colon and an elevated content of VIP
in dextran sulfate sodium (DSS)-induced colitis in rats
[51]. In contrast, Mazumdar and Das found decreased
expression of VIP immunoreactivity in the colon of both
CD and UC patients, compared to controls [52], while
two other studies showed a significant decreased of rectal
and colonic VIP in UC and CD patients.
The mechanism by which inflammation selectively
alters the expression of transmitters in the ENS is cur-
rently unknown; however, a recent study of TNBS colitis
in rats identified a role for nerve growth factor and its
receptors in susceptibility to inflammation-induced neu-
ronal damage.
In addition to SP and VIP, mRNA for a number of pep-
tides is increased in colon tissues from mice undergoing
experimental colitis induced by oil of mustard (OM; allyl
isothiocyanate), a direct stimulant of small nerve fibers
and a potent, acute inflammatory irritant. OM has been
used experimentally to evoke allodynia and visceral hype-
ralgesia following intracolonic administration to mice
[53]. Intracolonic application of a 0.5% solution of OM
produces a severe, transient colitis with the greatest dam-
age within the first three days.
OM colitis has a vital neuronal component, as evi-
denced by elevated expression of mu- and delta-opioids,
and the receptors NK1, cannabinoid receptor 1 (CB1R)
and TRPA1, the receptor for OM and a member of the
transient receptor potential channel family. TRPA1 is
responsible for detecting physical signals such as noxious
cold and directly contributes to the cold hyperalgesia
present in inflammatory states. Intrathecal injection of
TRPA1 antisense oligonucleotides, reduces TRPA1
expression and attenuates visceral hyperalgesia following
TNBS-induced colitis [54].
Neuronal receptor and neuropeptide mRNA expression
are upregulated within the first two hours following OM
colitis [53]. CB1R is transiently increased, consistent with
other reports related to pathways associated with pain
sensation stimulated by colitis, and also consistent with
data demonstrating increased CB1R expression in human
IBD.
Alterations in enteric neural signaling
A number of electrophysiological studies have been per-
formed in animal models of IBD in order to elucidate the
mechanisms underlying inflammation-induced changes
in gut motility. Independent of the method used to
induce colitis, the type of enteric neuron most dramati-
cally affected by inflammation is the afterhyperpolarizing
(AH) neuron.
In the normal guinea pig intestine, the AH neuron,
named for its prolonged afterhyperpolarization, func-
tions as an intrinsic primary afferent neuron in the myen-
t e ri c  p l e x u s  a n d  is  as socia t ed  wi t h  pe ri s t a ls is,  m u c os a l
secretion, and vasodilation. These neurons very rarely
receive fast synaptic inputs in normal conditions, but in
the guinea pig distal colon more AH neurons receive fast
synaptic inputs following the induction of inflammation
[55]. Similar findings have been reported for a T. spiralis
model of jejunitis. In this model, AH myenteric neurons
exhibit increased excitability, depolarized membrane
potential, and reduced AH potential amplitude and dura-
tion along with increased input resistance [56]. AH neu-
rons in the inflamed ileum also exhibit another form of
prolonged excitation, a prolonged hyperexcitability after
a brief stimulus that lasts up to three hours [57].Lakhan and Kirchgessner Journal of Neuroinflammation 2010, 7:37
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AH neurons characteristically receive slow excitatory
postsynaptic potentials (EPSPs) in the normal bowel.
However, maintained excitation that lasts from 27 min-
utes up to three hours occurs in AH neurons in inflamed
bowel [57]. Such long-term hyperexcitability is not
encountered in enteric neurons of normal intestine. The
maintained excitation indicates that a brief synaptic acti-
vation can trigger a long period of hyperexcitability in AH
neurons after they have been exposed to an inflamed
environment. These findings suggest that perturbation of
the sensory component of intrinsic motor reflexes may
occur during inflammation. Maintained neuronal excita-
tion, observed only in neurons from the inflamed bowel,
may contribute to the dysmotility, pain, and discomfort
associated with intestinal inflammation and IBD in par-
ticular. The mechanisms responsible for the changes in
excitability are not yet understood, but they may involve a
persistent alteration in channel expression and/or a con-
tinuous release of inflammatory mediators due to low-
grade inflammation.
Alterations in sympathetic neural activity
IBD alters the function of the ENS and the sensory inner-
vation of the GI tract. Less is known about whether IBD
affects the sympathetic nervous system, although experi-
mental evidence of sympathetic neural dysfunction in
IBD is increasing [58]. A decrease in the release of nora-
drenaline from sympathetic varicosities in inflamed and
un-inflamed regions of the GI tract has consistently been
r e p o r t e d  f o r  a n i m a l  m o d e l s  o f  c o l i t i s .  R e c e n t  f i n d i n g s
suggest that the decrease in neurotransmitter release may
be due to inhibition of N-type voltage-gated Ca2 c + cur-
rent in postganglionic sympathetic neurons [59]. How an
alteration of sympathetic function contributes to the
pathogenesis of IBD has not yet been determined.
Neuroimmune factors
It has been known for some time that the ENS and
mucosal immune systems have the ability to regulate one
another's functions. Nerve cells are found in close prox-
imity to immune cells in the mucosa. The two systems
even share several chemical mediators, such as SP. Neu-
ronal activation can lead to degranulation of mast cells
and influx of neutrophils, thereby recruiting elements of
innate immunity to the area. Lymphocytes express recep-
tors for neuropeptides released by enteric nerves, and
stimulation of these cells with SP or VIP can induce their
differentiation and alter their production of immuno-
globulins.
Signaling between immune cells and enteric neurons
can also evoke alterations in gut function. Linden et al.
indicated that the hyperexcitability of intrinsic primary
afferent neurons of inflamed guinea pig colon may be sec-
ondary to activation of cyclooxygenase (COX)-2 and pro-
duction of prostaglandins (PGE2) [60]. Alterations in
electrical and synaptic properties of enteric neurons in
non-inflamed colon of guinea pigs with TNBS-induced
ileitis are accompanied by significantly increased PGE2
tissue levels, despite the lack of overt inflammation in the
colon [61]. Moreover, these increased PGE2 levels are
attenuated in the presence of COX2 inhibitors.
Ileitis also increases the number of colonic 5-HT-
immunoreactive enteroendocrine cells and release of 5-
HT, despite the absence of inflammation in the colon.
Therefore, increased prostaglandin and 5-HT levels may
underlie some of the changes in neuronal properties
observed at sites of gut inflammation. These changes can
occur in non-involved regions during episodes of intesti-
nal inflammation.
Several studies point to the involvement of kinases in
the sustained changes that occur following inflammation
[62]. In previously inflamed colon, PKA activity in nerve
terminals increases and contributes to the facilitation of
fast synaptic transmission, possibly through inhibition of
big conductance K+  channels and an increase in the
release-ready pool of synaptic vesicles. In other studies,
inflammation of the small intestine induced by
Trichinella spiralis causes increased adenylyl cyclase
activity of myenteric neurons 6-9 days after infection
[63].
Mast cells
Mast cells and their chemicals have the potential to medi-
ate the effects of inflammation on enteric nerves because
they function as intermediaries between neurons and the
inflammatory soup in their environment [64]. Both mast
cells and neurons can be increased or decreased by an
inflammatory environment and, upon activation, release
mediators that can act on the gut neuromuscular appara-
tus. Although mast cells are most widely known for their
role in allergic responses, these cells are normally present
throughout the gut and are involved in a range of physio-
logical and pathological activities including mucosal
defense mechanisms and inflammation.
Enteric mast cells are concentrated with granules that
serve as sites of storage for a wide mix of preformed
chemical mediators. Antigens stimulate the mast cells to
release mediators, which then diffuse into the extracellu-
lar space to influence other cell types. Mast cells may
release an array of inflammatory mediators, which may
stimulate the residential macrophages on the one hand
and intrinsic and extrinsic neurons, on the other hand,
which may ultimately result in GI dysfunction and symp-
toms.
Mast cell degranulation evoked by psychological stress
activates an "alarm program" in the ENS to produce
symptoms of diarrhea and abdominal distress. Mast cells
are located close to enteric nerves and provide a struc-Lakhan and Kirchgessner Journal of Neuroinflammation 2010, 7:37
http://www.jneuroinflammation.com/content/7/1/37
Page 7 of 12
tural basis for communication between the gut and the
ENS. They release mediators, which signal the ENS that
degranulation has taken place while simultaneously
attracting immune/inflammatory cells into the intestinal
wall fr om t he mesent eric circula tion. Blockade of ENS
and sensory afferents by exposure of gut to the nerve
blocker tetrodotoxin, or application of mast cell stabiliz-
ing drugs, prevents the acute inflammatory response to
Clostridium difficile toxin-A. The terminals of vagal and
spinal afferent neurons also express receptors for mast
cell mediators.
There is considerable clinical evidence for mast cell
involvement in human IBD. In the colorectal mucosa
from patients with CD and UC, the amount of mast cell
tryptase is significantly increased as is the number of
mast cells in the lamina propria and submucosa [65].
Increased numbers of mast cells found in the colonic
mucosa of IBD patients are accompanied by dramatically
increased expression of TNF-alpha, IL-16, and SP [66].
Evidence of mast cell degranulation is found in the intes-
t i n a l  w a l l  o f  I B D  p a t i e n t s ,  s u g g e s t i n g  t h a t  m a s t  c e l l
degranulation is involved in the pathogenesis of IBD [66].
Infections with nematode parasites stimulate prolifera-
tion of mast cells in animals, which serve as experimental
models for the investigation of mast cell functions in
detection of and signaling the presence of sensitizing
antigens and infectious invaders that broach the mucosal
barrier.
Mast cells mediators include a number of proinflam-
matory substances (tryptase, histamine, platelet activat-
ing factor, prostaglandins, leukotrienes) and have the
capacity to produce a variety of cytokines. Mast cells
undergo degranulation during intestinal manipulation
and may be part of the mechanisms responsible for trig-
gering cellular infiltration and subsequent altered bowel
motility.
Evidence for communication between mast cells and
the ENS is derived from electrophysiological recordings
in enteric neurons in intestinal preparations from anti-
gen-sensitized animal models and recordings of the
actions of mast cell mediators on the electrical and syn-
aptic activity of ENS neurons. Several mast cell-derived
mediators have neuropharmacological actions on the
electrical and synaptic behavior of neurons in the ENS
including histamine, interleukin-6, leukotrienes, 5-HT,
platelet activating factor, mast cell proteases, adenosine,
interleukin-1β, and prostaglandins [67]. The evidence
suggests that mast cell signals trigger a neural program
for defensive intestinal behavior in response to circum-
stances within the lumen that are threatening the func-
tional integrity of the whole animal. Immunoneural
integration progresses sequentially beginning with
immune detection followed by signal transfer to the ENS,
and then by the selection of a specific neural program for
coordinated mucosal secretion and powerful propulsion
that effectively clears the antigenic threat from the intes-
tinal lumen [67].
Enterochromaffin cells
Studies show that intestinal inflammation is accompanied
by alterations in enteroendocrine cells. The 5-HT-con-
taining enterochromaffin (EC) cells are the most abun-
dant enteroendocrine cells present in the gut. They are
distributed throughout the GI tract, although the greatest
concentrations are located in the small intestine and rec-
tum. Ninety-five percent of GI tract 5-HT is found in EC
cells with the remainder within enteric neurons.
Enterochromaffin cells are interposed between gut epi-
thelial cells, where they act as sensors of the intraluminal
milieu. 5-HT release from EC cells is mediated by luminal
or neuronal stimuli that include stimuli such as mucosal
stroking, and endogenous chemical stimuli such as ade-
nosine. Following its release, 5-HT activates a variety of
receptors and participates in reflex propagation [68].
Enterochromaffin cells are influenced by GI inflamma-
tory conditions. Moreover, changes in the content,
release, and re-uptake of 5-HT have been reported in IBD
[69].
Mucosal EC cell number is increased in clinical and
experimental models of IBD [70]. Enterochromaffin cell
number is increased both in affected and non-affected
sites of the gut. A further factor that may act to increase
5-HT levels is that expression of the serotonin reuptake
transporter (SERT) is reduced.
The SERT molecule is a member of the Na+/Cl- neu-
rotransmitter transporter family and is expressed by epi-
thelial cells and neurons in the gut [68]. 5-HT is removed
from the interstitium by reuptake via SERT. These
changes are important due to the strategic location of EC
cells in the gut mucosa, making it likely that 5-HT has a
direct action on enteric neurons, regulating gut motility
and secretion [70]. Recently, Bischoff et al [71] demon-
strated that deletion of SERT increases the severity of
TNBS colitis in mice. These data suggest that 5-HT sig-
naling and its SERT-mediated termination may be
involved in the pathophysiology of IBD. There is evidence
that SERT expression is decreased in human IBD [41] as
well as in mice as a result of TNBS-induced colitis [71].
5-HT can modify gut motility/sensation is several ways.
5-HT is also present within enteric nerves [72]. It acts
upon 5-HT3 receptors of vagal afferent nerve fibers,
which in turn stimulate intestinal secretion and motor
reflexes. Furthermore, 5-HT can act on 5-HT3, 5-HT4,
and 5-HT1P receptors on enteric neurons thereby con-
tributing to peristalsis and stimulating intestinal transit
[73]. These findings implicate 5-HT signaling in theLakhan and Kirchgessner Journal of Neuroinflammation 2010, 7:37
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pathophysiology of IBD and suggest that drugs targeting
gut 5-HT receptors could benefit patients suffering from
inflammation-related gut disorders.
Other inflammatory cells in IBD
During an inflammatory flare, lymphocytes and other
inflammatory cells infiltrate the bowel wall, and both
local and circulating cytokine levels (e.g., Il1β, TNF-α, IL-
6 )  a r e  e l e v a t e d  i n  p a t i e n t s  w i t h  I B D .  T h e s e  cy t o k i n e s ,
secreted by circulating and resident inflammatory cells,
may exert direct influences on enteric nerves and are
capable of modulating its neuromuscular function.
In addition to increases in mast cells and EC cells, there
are trends for increases in CD3+ lymphocytes and the
proportion of lymphoid tissue. CD3 is a "pan T-lympho-
cyte marker" and allows one to estimate the overall num-
ber of T-lymphocytes in the lamina propria of patients
with IBD. It is possible that specific subclasses of lympho-
cytes may be altered in IBD (e.g., CD4+ T cells). Recently,
c i r c u l a t i n g  a n d  t i s s u e  B  c e l l s  f r o m  C D  p a t i e n t s  w e r e
shown to demonstrate elevated basal levels of activation
[74].
Post-inflammatory changes in gut function
There is no question that GI inflammation leads to signif-
icant changes in neuron-controlled gut functions, and
that alterations in gut function are accompanied by
changes in neurophysiological, neurochemical, and mor-
phological properties of enteric nerves. It has recently
become apparent that inflammatory changes persist fol-
lowing resolution of the initiating inflammatory event,
suggesting that prior inflammation can alter GI function
and visceral sensation.
In vivo, colitis causes impaired neurotransmitter func-
tion in both inflamed and noninflamed regions of the
bowel [75], and altered neuronal signaling can persist up
to eight weeks after the initiation of colitis, long after
inflammation is apparently resolved, according to histo-
logical examination and assay of myeloperoxidase activity
in tissue extracts [76]. Other animal models also show
that neural function can remain affected by prior damage
for extended periods of time, such as the impaired ACh
metabolism seen at least six months after Trichinella spi-
ralis-induced intestinal inflammation [77]. This implies
that the inflammation may cause a prolonged change in
the intrinsic properties of the neurons. What mediates
the persistent post-inflammatory hyperexcitability of
enteric neurons is not yet known. However, increased
numbers of immune cells in the human rectal mucosa
have been documented for at least a year after an acute
infection with Campylobacter enteritis [78].
A surge of eosinophils and T-lymphocytes associated
with the enteric ganglia occurs at 1-7 days following
TNBS colitis [31]. However, elevated immune cell num-
bers occur in the lamina propria of the mucosa until 56
days. Thus, ongoing mucosal inflammatory reaction may
contribute to the persistence of enteric neuropathy. This
makes sense, since the major neuron type in myenteric
ganglia whose properties are changed by a brief severe
inflammation are the AH neurons [55]. These neurons
have processes in the mucosa that are stimulated by local
mediators, for example 5-HT. The exposure of their nerve
terminal in the mucosa to the products of the immune
cells may contribute to the maintenance of increased
excitability of AH neurons. Questions remain as to what
genes are being activated or inactivated, and as to how
these genes might be influenced to return to normal lev-
els of activity.
Oxidative stress
It is generally hypothesized that IBD is caused by GI tract
immune dysregulation, because the disease is accompa-
nied by a considerable infiltration of inflammatory cells
in the gut mucosa [79]. However, the specific pathways
leading to cellular damage have yet to be fathomed. Oxi-
dative stress is a potential biological and/or triggering
factor for IBD, because the detrimental effects of reactive
oxygen species (ROS) are well established in the inflam-
mation process.
Oxidative stress arises when there is a marked imbal-
ance between the production of ROS and their removal
by antioxidants. In reaction to mild oxidative stress, tis-
sues often respond by producing more antioxidants; how-
ever, severe persistent oxidative stress depletes body
antioxidant resources and overtakes its ability to produce
more antioxidants, leading to lower antioxidant levels
and injury in the tissues.
For example, patients with IBD demonstrate decreased
expression of the anti-oxidant heme-oxygenase-1 (HO-1)
in the intestinal epithelium of inflamed colonic mucosa,
compared to control specimens, suggesting dysregulated
expression in inflammation [80]. HO-1 is the rate-limit-
ing enzyme in the catabolism of heme, which leads to the
generation of biliverdin, iron, and carbon monoxide and
has been shown to have important anti-inflammatory
properties. Moreover, induction of HO-1 protects neu-
rons from oxidative stress-induced cell death, possibly in
response to activation of the transcription factor Nrf2
[81].
In vivo, induction of HO-1 by the HO-1 inducer cobalt
protoporphyrin (CoPP) leads to significant down-regula-
tion of colonic inflammation in acute DSS-induced colitis
[80]. Moreover, the protective effects of HO-1 in experi-
mental colitis are replicated by administration of hemin,
which markedly reduces programmed cell death of
colonic epithelium and attenuates the production of
interleukin 17 [82]. In addition, rectal administration of
tranilast, a mast cell stabilizer, significantly increasesLakhan and Kirchgessner Journal of Neuroinflammation 2010, 7:37
http://www.jneuroinflammation.com/content/7/1/37
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expression of HO-1 in colonic epithelial cells and is
thought to mediate the anti-inflammatory effects of tra-
nilast in DSS colitis and human IBD [83].
In addition to colonic epithelial cells, HO-1 is expressed
in macrophages. In both mouse and human colon, HO-1
immunoreactivity is displayed by macrophages in close
proximity to SP-containing nerve fibers (Figure 1). Mac-
rophages have pro- and anti-inflammatory activities,
depending on their phenotype. For example, CD206+/
HO-1+  gastric macrophages protect against oxidative
stress-induced damage and are required for prevention of
diabetic gastroparesis in mice [84]. Thus, expression of
HO-1 in macrophages could constitute an important
component of the anti-inflammatory effect by increasing
antioxidant protection and decreasing the inflammatory
component of IBD lesions. Moreover, the expression of
HO-1 in macrophages close to enteric nerves could act as
a natural defense mechanism to alleviate enteric nerve
injury in the GI tract. Therefore, induction of HO-1
expression in macrophages might be a therapeutic option
to protect neurons in patients with IBD; however, this
idea remains to be tested.
The presence of reactive oxygen metabolites, or the
molecules damaged by them, has been extensively stud-
ied in patients with IBD [85]. Although some results are
conflicting, it seems that patients with IBD demonstrate
excessive oxidized molecules compared with healthy con-
trol subjects in a variety of organ systems. This seems to
be  m or e  pr onou nc ed in pa ti en ts wit h CD .  In fact,  t he
most commonly used drug for patients with IBD, 5-amin-
osalicylic acid, has ROS scavenging capabilities [86].
Similar results have been found in animal models of
IBD, which universally show abnormal levels of antioxi-
dants or oxidized molecules [85]. The most striking evi-
dence comes from genetic knockout mice lacking the
antioxidant enzyme of glutathione peroxidase. These ani-
mals display destructive colitis similar to UC as early as
11 days of age [87].
Activation of immune cells and the release of ROS such
as H2O2 are prominent early events in the pathogenesis of
IBD that could affect the ENS. There is a close parallel
between the loss of enteric neurons and their axons after
exposure to H2O2 observed in vitro, and the damage to
the ENS that is seen in the acute phase of initiation of
colitis in vivo, where a significant loss of neurons occurs
by 24 h [24]. The damage produced by H2O2 does not tar-
get a specific neuronal phenotype as the death of myen-
teric neurons is distributed equally among cholinergic
and nitrergic neurons. Thus, the neurotoxic events of
inflammation appear to be nonselective.
A comparison of ROS levels, using DHR fluorescence,
in preparations of myenteric plexus from 12- to 15-
month-old rats showed increased levels of free radical
generation with age, suggesting that aging correlates with
higher levels of intrinsic neuronal ROS. Interestingly, ele-
vated levels of intraneuronal ROS are correlated with
substantial neuron loss suggesting a plausible mechanism
whereby age-related neuron cell death is produced [88].
Enhanced ROS production and oxidative injury play a
cardinal role in the onset and progression of neurodegen-
erative disorders. To maintain a proper redox balance, the
CNS is equipped with an antioxidant defense mechanism
consisting of endogenous antioxidant enzymes. The
expression of most antioxidant enzymes is tightly con-
trolled by the antioxidant response element (ARE) and is
activated by Nrf2, a transcription factor that regulates an
expansive set of antioxidant genes that act in synergy to
remove ROS through sequential enzymatic reactions.
When activated, Nrf2 specifically targets genes bearing
an ARE within their promoters such as HO-1, 1-ferritin,
and glutathione peroxidase, which maintain redox
homeostasis and influence the inflammatory response.
Not surprisingly, Nrf2-deficient mice have an increased
susceptibility to DSS-induced colitis, possibly due to
reduced expression of antioxidant phase II detoxifying
enzymes with a concomitant increased induction of
proinflammatory mediators [89]
Several of the genes commonly regulated by Nrf2 have
been implicated in protection from neurodegenerative
conditions. For this reason, Nrf2 may be considered a
therapeutic target for conditions that are known to
involve free radical damage. Mitochondrial dysfunction
Figure 1 Immunoreactivity to hemeoxygenase-1 (HO-1) and sub-
stance P (SP) in a cryostat section of human colon. An HO-1-posi-
tive macrophage (orange) is seen in close proximity to a SP-containing 
nerve fiber (green) in the colonic mucosa.Lakhan and Kirchgessner Journal of Neuroinflammation 2010, 7:37
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and build-up of ROS are indicative of neurodegeneration;
therefore, targeting Nrf2 may be valuable in combating
neurodegeneration in IBD.
Neuroprotection by enteric glial cells
Enteric glial cells have recently been postulated to have a
novel neuroprotective role in the ENS. Enteric glial cells
are analogous to, and share many similarities with, astro-
cytes of the CNS. Following major ablation of enteric glial
cells, there is a significant decrease in the number of
myenteric neurons compared to control [90]. Notably,
there is a loss of NOS-containing neurons in the myen-
teric plexus, which likely underlies disturbances observed
in smooth muscle relaxation and intestinal transit time.
The mechanisms responsible for neuronal cell loss
remain unknown. However, this may be due to reduced
availability of neuroprotective factors, which could lead
to an increase in susceptibility of enteric neurons to
insults such as oxidative stress, as occurs in IBD.
Enteric glial cells are known to actively participate in
inflammatory processes. They produce and respond to an
array of cytokines. They also protect neurons from oxida-
tive stress in part via reduced glutathione (GSH) [91].
GSH has been identified in the CNS as being synthesized
by astrocytes and exerting neuroprotective effects, espe-
cially during oxidative stress [92].
Conclusion
This review describes changes in the anatomical and
physiological properties of enteric neurons in response to
gut inflammation. In general, inflammation-related
changes in GI function likely involve neurodegeneration
and neuroplasticity in the ENS, as well as changes in the
structure and function of enteric glia. Although the
mechanisms involved in modulation of enteric neural
activity during inflammation are not completely under-
stood, oxidative stress appears to play an important role
in the process. Thus, it is possible that neuroprotective
agents that curtail oxidative stress in the ENS could
restore gut function and could have utility in the treat-
ment of gut dysfunction in IBD.
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